Related Experiment Video
Updated: Feb 18, 2026

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
Published on: September 22, 2011
High-Throughput Process Development for Biopharmaceuticals
Abhinav A Shukla1, Shahid Rameez2, Leslie S Wolfe2
1Process Development and Manufacturing, KBI Biopharma Inc., 2 Triangle Drive, Research Triangle Park, Durham, NC, 27709, USA. ashukla@kbibiopharma.com.
Abstract:
The ability to conduct multiple experiments in parallel significantly reduces the time that it takes to develop a manufacturing process for a biopharmaceutical. This is particularly significant before clinical entry, because process development and manufacturing are on the "critical path" for a drug candidate to enter clinical development. High-throughput process development (HTPD) methodologies can be similarly impactful during late-stage development, both for developing the final commercial process as well as for process characterization and scale-down validation activities that form a key component of the licensure filing package. This review examines the current state of the art for HTPD methodologies as they apply to cell culture, downstream purification, and analytical techniques. In addition, we provide a vision of how HTPD activities across all of these spaces can integrate to create a rapid process development engine that can accelerate biopharmaceutical drug development. Graphical Abstract.

